ReviewACS omega2025
The Role of ROS in Atherosclerosis and ROS-Based Nanotherapeutics for Atherosclerosis: Atherosclerotic Lesion Targeting, ROS Scavenging, and ROS-Responsive Activity.
Review in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dysregulated Redox Signaling and Its Impact on Inflammatory Pathways, Mitochondrial Dysfunction, Autophagy and Cardiovascular Diseases.Antioxidants (Basel, Switzerland) · 2025Review
- Are an Aging Gut and a Decrease in Butyrate Production the Reasons for Atherosclerosis?International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis is a progressive inflammatory disease that is intimately associated with oxidative stress. Reactive oxygen species (ROS) are involved in various critical stages of atherogenesis including endothelial dysfunction, immune cell activation, and foam cell formation. In recent years, nanotherapeutic approaches have emerged as promising tools to regulate ROS levels due to their tunable physicochemical properties, stimuli-responsiveness, and lesion-targeting potential. This review presents an integrated summary of ROS generation and elimination mechanisms in atherosclerotic plaques and outlines recent developments in both ROS-scavenging and ROS-responsive nanoplatforms. Instead of viewing these approaches in isolation, we emphasize their combinatorial potential to enhance therapeutic precision. Key challenges, including biosafety, pharmacokinetics, and off-target effects, are critically discussed. Lastly, we provide perspectives on the future design of intelligent, multifunctional, and clinically translatable ROS-modulating nanotherapeutics for effective atherosclerosis treatment.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.